SILENCE THER. (SLN)

 

Latest News

Silence Therapeutics provides litigation update

Silence Therapeutics said it has served is defense in actions initiated by Alnylam and The Medicines Company. Previously, ...

Update on litigation matters

RNS Number: 8685W Silence Therapeutics PLC 20 November 2017 Update on litigation matters 20 November 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces an update on litigation matters. P...

Capital Markets Day

RNS Number: 3663W Silence Therapeutics PLC 14 November 2017 Silence Therapeutics ' 2017 Capital Markets Day 14 November 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, will today host a Capital M...

Silence Therapeutics provides litigation update

Silence Therapeutics expressed confidence that it would emerge successfully from litigation in the UK over a patent disput...

All News

DateHeadlineSource
20-11-17Silence Therapeutics provides litigation updateStockMarketWire
20-11-17Update on litigation mattersRNS
14-11-17Capital Markets DayRNS
03-11-17Silence Therapeutics provides litigation updateStockMarketWire
03-11-17Update on Litigation MattersRNS
02-11-17Second Price Monitoring ExtnRNS
02-11-17Price Monitoring ExtensionRNS
26-10-17Holding(s) in CompanyRNS
24-10-17Holding(s) in CompanyRNS
19-10-17Holding(s) in CompanyRNS
18-10-17Holding(s) in CompanyRNS
18-10-17Silence Therapeutics granted US patentsStockMarketWire
18-10-17Further US patents grantedRNS
17-10-17Serving of claim in the UK High CourtRNS
16-10-17Silence Therapeutics appoints new chairmanStockMarketWire
16-10-17Appointment of Non-Executive ChairRNS
11-10-17Silence Therapeutics granted US patentStockMarketWire
11-10-17Key US patent grantedRNS
06-10-17Holding(s) in CompanyRNS
28-09-17Holding(s) in CompanyRNS
27-09-17Holding(s) in CompanyRNS
27-09-17Holding(s) in CompanyRNS
26-09-17Holding(s) in CompanyRNS
22-09-17Holding in CompanyRNS
22-09-17Holding in CompanyRNS
22-09-17Holding in CompanyRNS
22-09-17Holding in CompanyRNS
22-09-17Holding in CompanyRNS
20-09-17Second Price Monitoring ExtnRNS
20-09-17Price Monitoring ExtensionRNS
13-09-17Second Price Monitoring ExtnRNS
13-09-17Price Monitoring ExtensionRNS
11-09-17Silence patents approvedStockMarketWire
11-09-17Further Strengthens US Patent EstateRNS
08-09-17Second Price Monitoring ExtnRNS
08-09-17Price Monitoring ExtensionRNS
06-09-17Silence Therapeutics makes progress on drug pipelineStockMarketWire
06-09-17Interim results for six months ended 30 June 2017RNS
04-09-17Notice of Interim ResultsRNS
23-08-17Save the Date: Capital Markets Event 14 NovemberRNS

RSS feeds

  • Editorial news feed for LSE:SLN Editorial
  • Regulatory news feed for LSE:SLN Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account